CLINICAL VIROLOGY MANUAL
FIFTH EDITION
DEDICATION

We dedicate this edition of the Clinical Virology Manual to our families for their patience and support during this and our other professional endeavors. We are truly blessed to be part of their lives and to receive their unconditional love.

We would also like to thank, and gratefully acknowledge the support and leadership of, our close colleague, mentor, and friend, Dr. Steven Specter, who has worked tirelessly over the years in delivering the first four editions of the Manual, to advance the field of viral diagnostics, and to provide a forum for clinical virologists, academicians, and clinicians to present and discuss the latest scientific discoveries. We will be forever appreciative of his unwavering efforts.
Contents

SECTION I ________________________________

GENERAL TOPICS IN CLINICAL VIROLOGY

1 The Taxonomy, Classification, and Characterization of Medically Important Viruses / 3
STEVEN J. DREWS

2 Quality Assurance and Quality Control in Clinical and Molecular Virology / 27
MATTHEW J. BANKOWSKI

3 Regulatory Compliance / 35
LINOJ SAMUEL

4 Laboratory Safety / 41
K. SUE KEHL

5 Laboratory Design / 51
MATTHEW J. BINNICKER

SECTION II ________________________________

LABORATORY PROCEDURES FOR DETECTING VIRUSES

6 Specimen Requirements Selection, Collection, Transport, and Processing / 59
REETI KHARE AND THOMAS E. GRYS

7 Primary Isolation of Viruses / 79
MARIE L. LANDRY AND DIANE LELAND

8 Viral Antigen Detection / 95
DIANE S. LELAND AND RYAN F. RELICH

9 Serologic (Antibody Detection) Methods / 105
DONGXIANG XIA, DEBRA A. WADFORD, CHRISTOPHER P. PREAS, AND DAVID P. SCHNURR

10 Nucleic Acid Extraction in Diagnostic Virology / 117
RAYMOND H. WIDEN AND SUZANE SILBERT

11 Nucleic Acid Amplification by Polymerase Chain Reaction / 129
ANA MARÍA CÁRDENAS AND KEVIN ALBY

12 Isothermal Nucleic Acid Amplification Methods / 137
HARALD H. KESSLER AND EVELYN STELZL

13 Quantitative Molecular Methods / 145
NATALIE N. WHITFIELD AND DONNA M. WOLK

14 Signal Amplification Methods / 167
YUN (WAYNE) WANG

15 DNA Sequencing for Clinical and Public Health Virology: Some Assembly Required / 173
JOANNE BARTKUS

16 Phenotypic and Genotypic Antiviral Susceptibility Testing / 201
MARTHA T. VAN DER BEEK AND ERIC C. J. CLAAS
17 Point-of-Care Diagnostic Virology / 229
JAMES J. DUNN AND LAKSHMI CHANDRAMOHAN

18 Future Technology / 243
ERIN MCELVANIA TEKIPPE AND CAREY-ANN D. BURNHAM

SECTION III

VIRAL PATHOGENS

19 Respiratory Viruses / 257
CHRISTINE ROBINSON, MICHAEL J. LOEFFELHOLZ, AND BENJAMIN A. PINSKY

20 Enteroviruses and Parechoviruses / 277
M. STEVEN OBERSTE AND MARK A. PALLANSCH

21 Measles, Mumps, and Rubella Viruses / 293
WILLIAM J. BELLINI, JOSEPH P. ICENOGLE, AND CAROLE J. HICKMAN

22 Gastrointestinal Viruses / 311
MICHAEL D. BOWEN

23 Hepatitis A and E Viruses / 329
GILBERTO VAUGHAN AND MICHAEL A. PURDY

24 Hepatitis B and D Viruses / 341
REBECCA T. HORVAT

25 Hepatitis C Virus / 351
MELANIE MALLORY AND DAVID HILLYARD

26 Herpes Simplex Viruses and Varicella Zoster Virus / 363
SCOTT H. JAMES AND MARK N. PRICHARD

27 Cytomegalovirus / 373
PREETI PANCHOLI AND STANLEY I. MARTIN

28 Epstein-Barr Virus / 387
DERRICK CHEN AND BELINDA YEN-LIEBERMAN

29 Human Herpesviruses 6, 7, and 8 / 399
SHEILA C. DOLLARD AND TIMOTHY M. KARNAUCHOW

30 Human Papillomaviruses / 413
SUSAN NOVAK-WEEKLEY AND ROBERT PRETORIUS

31 Human Polyomaviruses / 427
REBECCA J. ROCKEET, MICHAEL D. NISSEN, THEO P. SLOOTS, AND SEWERYN BIALASIEWICZ

32 Parvoviruses / 443
RICHARD S. BULLER

33 Poxviruses / 457
ASHLEY V. KONDAS AND VICTORIA A. OLSON

34 Rabies Virus / 473
ROBERT J. RUDD AND APRIL D. DAVIS

35 Arboviruses / 493
LAURA D. KRAMER, ELIZABETH B. KAUFFMAN, NORMA P. TAVAKOLI

36 Animal-Borne Viruses / 515
GREGORY J. BERRY, MICHAEL J. LOEFFELHOLZ, AND GUSTAVO PALACIOS

37 Human Immunodeficiency Viruses and Human T-lymphotropic Viruses / 527
JÖRG SCHÜPBACH

38 Chlamydiae / 545
BARBARA VAN DER POL AND CHARLOTTE A. GAYDOS

39 The Human Virome / 561
MATTHEW C. ROSS, NADIM J. AJAMI, AND JOSEPH F. PETROSINO

40 Human Susceptibility and Response to Viral Diseases / 567
VILLE PELTOLA AND JORMA ILONEN

APPENDIXES: REFERENCE VIROLOGY LABORATORIES

APPENDIX 1 Reference Virology Laboratory Testing Performed at the Centers for Disease Control / 581
ROBERTA B. CAREY

APPENDIX 2 Public Health Laboratory Virology Services / 585
JANE GETCHELL

APPENDIX 3 International Reference Laboratories Offering Virology Services / 595
ARIEL I. SUAREZ AND CRISTINA VIDELA

INDEX / 607
Contributors

NADIM AJAMI
Baylor College of Medicine, Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and Microbiome Research Houston, TX 77030

KEVIN ALBY
University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, PA 19104

MATTHEW J. BANKOWSKI
Diagnostic Laboratory Services (The Queen's Medical Center) Aiea, HI 96701

JOHN A. BURNS
School of Medicine, Department of Pathology, University of Hawaii at Manoa Honolulu, HI 96813

JOANNE BARTKUS
Minnesota Department of Health, Public Health Laboratory St Paul, MN 55164

WILLIAM BELLINI
Centers for Disease Control and Prevention, MMRHLB/DVD/NCIRD Atlanta, GA 30329

GREGORY BERRY
University of Texas Medical Branch, Clinical Microbiology Laboratory Galveston, TX 77555

SEWERYN BIALASIEWICZ
Centre for Children's Health Research, Children's Health Queensland, and the Child Health Research Centre, The University of Queensland South Brisbane, QLD 4101 Australia

MATTHEW J. BINNICKER
Mayo Clinic, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology Rochester, MN 55905

MICHAEL D. BOWEN
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases Atlanta, GA 30333

RICHARD BULLER
Washington University School of Medicine, Department of Pediatrics Saint Louis, MO 63110

CAREY-ANN BURNHAM
Washington University School of Medicine, Department of Pathology & Immunology Saint Louis, MO 63110

ANA MARIA CARDENAS
University of Pennsylvania, Department of Pathology and Laboratory Medicine Philadelphia, PA 19103

ROBERTA CAREY
Centers for Disease Control and Prevention, Laboratory Quality Management Atlanta, GA 30333

LAKSHMI CHANDRAMOHAN
Texas Children's Hospital, Department of Pathology Houston, TX 77030

DERRICK CHEN
Mayo Clinic, Laboratory Medicine and Pathology Rochester, MN 55905

ERIC C.J. CLAAS
Leiden University Medical Centre, Medical Microbiology Leiden 2333 ZA

APRIL DAVIS
New York State Health Department, Wadsworth Center Slingerlands, NY 12159

SHEILA C. DOLLARD
Centers for Disease Control and Prevention, Division of Viral Diseases Atlanta, GA 30329

STEVEN J. DREWS
ProvLab Alberta, Diagnostic Virology University of Alberta, Department of Laboratory Medicine and Pathology Edmonton, AB Canada
CONTRIBUTORS

JAMES DUNN
Texas Children's Hospital, Department of Pathology Houston, TX 77030

CHARLOTTE GAYDOS
Johns Hopkins University School of Medicine, Division of Infectious Diseases Baltimore, MD 21205

JANE GETCHELL
Public Health Laboratory Consultant Bethany Beach, DE 19930

THOMAS GRYS
Mayo Clinic in Arizona, Department of Laboratory Medicine and Pathology Phoenix, AZ 85054

CAROLE HICKMAN
Centers for Disease Control and Prevention, MMRHLB/DVD/NCIRD Atlanta, GA 30329

REBECCA HORVAT
University of Kansas Medical Center, Department of Pathology Kansas City, Kansas 66160

JOSEPH ICENOGLE
Centers for Disease Control and Prevention, MMRHLB/DVD/NCIRD Atlanta, GA 30329

JORMA ILONEN
University of Turku, The Immunogenetics Laboratory Turku, Finland

SCOTT JAMES
University of Alabama at Birmingham, Department of Pediatrics Birmingham, AL 35233

TIMOTHY KARNAUCHOW
Children's Hospital of Eastern Ontario, Division of Virology Ottawa, Ontario K1H 8L1 Canada

ELIZABETH KAUFFMAN
New York State Department of Health, Wadsworth Center Slingerlands, NY 12159

SUE KEHL
Medical College of Wisconsin, Department of Pathology Milwaukee, WI 53226

HARALD KESSLER
Medical University of Graz Graz, Austria

REETI KHARE
Northwell Health Laboratories, Department of Pathology and Laboratory Medicine Lake Success, NY 11042

ASHLEY KONDAS
Centers for Disease Control and Prevention, Poxvirus and Rabies Branch Atlanta, GA 30333

LAURA KRAMER
New York State Department of Health, Wadsworth Center, and Department of Biomedical Sciences, SUNY Albany Slingerlands, NY 12159

MARIE LOUISE LANDRY
Yale University, Departments of Laboratory Medicine and Internal Medicine (Infectious Diseases) New Haven, CT 06520

DIANE LELAND
Indiana University School of Medicine, Department of Pathology and Laboratory Medicine Indianapolis, IN 46202

MICHAEL LOEFFELHOLZ
University of Texas Medical Branch, Clinical Microbiology Laboratory Galveston, TX 77555

STANLEY MARTIN
The Ohio State University Wexner Medical Center, Division of Infectious Diseases; Transplant Infectious Diseases Service Columbus, OH 43210

MICHAEL NISSEN
Children's Health Queensland, Queensland Children's Medical Research Institute Brisbane, Queensland 4029 Australia

SUSAN NOVAK-WEEKLEY
Southern California Permanente Medical Group, Regional Reference Laboratories, Microbiology North Hollywood, CA 91605

M. STEVEN OBERSTE
Centers for Disease Control and Prevention, Poxvirus and Rabies Branch Atlanta, GA 30333

VICTORIA OLSON
Centers for Disease Control and Prevention, Poxvirus and Rabies Branch Atlanta, GA 30333

GUSTAVO PALACIOS
USAMRIID, Center for Genome Sciences Frederick, MD 21702

MARK PALLANSCH
Centers for Disease Control and Prevention, Division of Viral Diseases Atlanta, GA 30329

PREETI PANCHOLI
The Ohio State University Wexner Medical Center, Department of Pathology Columbus, OH 43205

VILLE PELTOLA
Turku University Hospital, Department of Pediatrics and Adolescent Medicine Turku 20521 Finland

JOSEPH PETROSINO
Baylor College of Medicine, Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and Microbiome Research Houston, TX 77030

CHRISTOPHER PREAS
California Department of Public Health, Viral and Rickettsial Disease Laboratory Richmond, CA 94804

ROBERT PRETORIUS
Southern California Permanente Medical Group—Fontana, Obstetrics and Gynecology Fontana, CA 92445

MARK PRICHARD
University of Alabama at Birmingham, Department of Pediatrics Birmingham, AL 35233

MICHAEL PURDY
Centers for Disease Control and Prevention, Division of Viral Hepatitis Atlanta, GA 30329
CONTRIBUTORS

RYAN RELICH
Indiana University School of Medicine, Department of Pathology and Laboratory Medicine Indianapolis, IN 46202

REBECCA ROCKETT
Centre for Infectious Diseases & Microbiology - Public Health (CIDM-PH) Institute of Clinical Pathology & Medical Research (ICPMR) Westmead Hospital, Westmead NSW, 2145, Sydney, Australia

MATTHEW ROSS
Baylor College of Medicine, Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and Microbiome Research Houston, TX 77030

ROBERT RUDD
New York State Health Department, Wadsworth Center Slingerlands, NY 12159

LINOJ SAMUEL
Henry Ford Health System, Department of Pathology Detroit, MI 48202

DAVID SCHNURR
California Department of Public Health, Viral and Rickettsial Disease Laboratory Richmond, CA 94804

JÖRG SCHÜPBACH
University of Zurich, Institute of Medical Virology, Swiss National Center for Retroviruses Zurich CH-8057 Switzerland

SUZANE SILBERT
Tampa General Hospital, Department of Pathology, Esoteric Testing/R&D Tampa, FL 33606

THEO SLOOTS
Centre for Children’s Health Research, Children’s Health Queensland, and the Child Health Research Centre, The University of Queensland South Brisbane, QLD 4101 Australia

EVELYN STELZL
Medical University of Graz Graz, Austria

ARIEL SUAREZ
IACA Laboratorios, Molecular Biología Bahía Blanca, Buenos Aires B8000FIB Argentina

NORMA TAVAKOLI
New York State Department of Health, Wadsworth Center, And Department of Biomedical Sciences, State University of New York Albany, NY 12208

ERIN MCELVANIA TEKIPPE
University of Texas Southwestern Medical Center, Department of Pathology and Pediatrics Dallas, TX

MARTHA T. VAN DER BEEK
Leiden University Medical Centre, Medical Microbiology Leiden 2333 ZA Netherlands

BARBARA VAN DER POL
University of Alabama at Birmingham School of Medicine, Division of Infectious Diseases Birmingham, AL 35294

GILBERTO VAUGHAN
Centers for Disease Control and Prevention, Division of Viral Hepatitis Atlanta, GA 30329

CRISTINA VIDELEA
CEMIC Virology Buenos Aires C1431FWO Argentina

DEBRA WADFORD
California Department of Public Health, Viral and Rickettsial Disease Laboratory Richmond, CA 94804

YUN F. WANG
Emory University School of Medicine, Department of Pathology & Laboratory Medicine Atlanta, GA 30303

NATALIE WHITFIELD
OpGen Clinical Services Laboratory Gaithersburg, MD 20878

RAYMOND WIDEN
Tampa General Hospital, Pathology Department, Esoteric Testing/R&D Tampa, FL 33606

DONNA WOLK
Geisinger Health Systems, Dept. of Laboratory Medicine Danville, PA 17822

DONGXIANG XIA
California Department of Public Health, Viral and Rickettsial Disease Laboratory Richmond, CA 94804

BELINDA YEN-LIEBERMAN
Cleveland Clinic, Laboratory Medicine Cleveland, OH 44195
Editor Biographies

Michael J. Loeffelholz is a Professor in the Department of Pathology, Director of the Clinical Microbiology Laboratory at the University of Texas Medical Branch (UTMB) at Galveston, and Director of the American Society for Microbiology (ASM) CPEP-accredited Medical Microbiology Fellowship program at UTMB. Dr. Loeffelholz is also an editor of the *Journal of Clinical Microbiology*. He has served on a number of committees, including the Pan American Society for Clinical Virology (PASCV), ASM Committee on Professional Affairs, CDC Board of Scientific Counselors/Office of Infectious Diseases, and the Association of Public Health Laboratories Board of Directors. Dr. Loeffelholz is a diplomate of the American Board of Medical Microbiology (ABMM).

Richard L. Hodinka is a Professor in the Microbiology Department and Chair of the Department of Biomedical Sciences at the University of South Carolina School of Medicine, Greenville. Dr. Hodinka's clinical and research interests involve pediatric viral diseases, detection and monitoring of viral infections in pediatric and adult immunocompromised hosts, and the development and study of rapid and accurate methods for the diagnosis of infectious diseases; current emphasis is on molecular technologies and automated instrumentation for the greatest impact on the care and management of ill patients. Dr. Hodinka has served as President and a Council Member for the PASCV, as a member of the International Scientific Advisory Committee for the Asia Pacific Congress of Medical Virology, and on a number of ASM committees. Dr. Hodinka has published extensively and is the author of a number of original scientific publications, review articles, and book chapters.

Stephen A. Young is Director of Research and Clinical Trials at TriCore Reference Laboratories and Professor (emeritus) in the Department of Pathology at the University of New Mexico. Dr. Young served as a collaborator in the Multi-Center AIDS Cohort Study for 25 years and is a co-investigator on two NIH grants affiliated with the cohort. He is involved in an active research program to evaluate and develop diagnostic products for clinical microbiology and has completed approximately 100 FDA in vitro diagnostic device trials or market evaluations of diagnostic tests. Dr. Young is a diplomate of the ABMM.

Benjamin A. Pinsky is an Assistant Professor in the Departments of Pathology and Medicine, Division of Infectious Diseases and Geographic Medicine, at the Stanford University School of Medicine and is the Medical Director of the Clinical Virology Laboratory for Stanford Health Care and Stanford Children's Health. Dr. Pinsky is on the editorial boards of several journals including the *Journal of Clinical Microbiology* and *Clinical Microbiology Reviews*. He has also served on a number of committees, including the PASCV, College of American Pathologists Microbiology Resource Committee, and the Association for Molecular Pathology Clinical Practice Committee. Dr. Pinsky is board certified in Clinical Pathology by the American Board of Pathology.
Preface to the Fifth Edition

The aims of the fifth edition of the Clinical Virology Manual remain the same as prior editions and include serving as a reference source to healthcare professionals and laboratorians in providing clinical and technical information regarding viral diseases and the diagnosis of viral infections.

This new edition includes 40 chapters and 3 appendices and, similar to the organization of prior additions, consists of the four sections: general topics, laboratory procedures, viral pathogens, and the appendices. We have modified the content of the appendices to provide basic but practical information on reference virology laboratories at both the national and international levels. The viral pathogen chapters have a consistent organization, with proportionally more content dedicated to diagnostics and testing. Additionally, a new section, with the heading of “Diagnostic Best Practices”, has been included in each viral pathogens chapter. The section summarizes recommendations for diagnostic testing and cites evidence-based guidelines when available.

The past several years have been very challenging, as well as exciting, for diagnostic virologists, with outbreaks of enterovirus D68, measles virus, mumps virus, norovirus, Ebola virus, and, most recently, Zika virus. In addition, there is continued emergence of chikungunya, dengue, and influenza viruses, highlighted by the influenza pandemic of 2009. The landscape of hepatitis C virus has changed, and will continue to change dramatically, with the availability of new classes of direct-acting antiviral drugs that provide an excellent probability of cure.

This edition has incorporated these significant events to the extent allowed by the production schedule. We thank the authors for their contributions, particularly during this very busy time for virologists. We also thank the staff of the American Society for Microbiology Press for their support and hard work in bringing this edition to fruition.

The fifth edition of the Manual also brings a major change in editors, as a new editor has been added and a previous editor has cycled off. Also, after successfully leading this series through four editions, Dr. Steven Specter has passed on the reins of Editor-in-Chief. We hope that this edition is a credit to Dr. Specter, as well as to other prior editors, Drs. Lancz and Wiedbrauk.

MICHAEL J. LOEFFELHOLZ
RICHARD L. HODINKA
STEPHEN A. YOUNG
BENJAMIN A. PINSKY
Subject Index

A
ABI SOLiD, 179
Abnova, 123
Acquired immunodeficiency syndrome (AIDS)
cytomegalovirus infection with, 381
HIV-6 in patients with, 69
ACS. See American Cancer Society
Acute bronchitis, 9
Acute cardiovascular diseases, 9
Acute diarrhea, 9
Acute gastroenteritis, 9, 12
Acute hemorrhagic conjunctivitis, 9
Acute myocarditis, enteroviruses with, 283
Acute respiratory infections, 9
Acute respiratory infections in children, 296
Acute respiratory infections in infants, 296
Acute respiratory infections in neonates and infants, 297
Acute respiratory infections in neonates with respiratory syncytial virus, 297
Acute respiratory infections in neonates with severe acute respiratory syndrome, 297
Acute respiratory infections in neonates with unexpected respiratory syncytial virus infection, 297
Acute respiratory infections in neonates with viral lower respiratory tract infections, 297
Acute respiratory infections in older adults, 296
Acute respiratory infections in immunocompromised hosts, 296
Acute respiratory infections in immunocompromised hosts with immunosuppressive therapy, 296
Acute respiratory infections in immunocompromised hosts with lymphoma, 296
Acute respiratory infections in immunocompromised hosts with myeloid malignancies, 296
Acute respiratory infections in immunocompromised hosts with myeloid malignancies and lymphoma, 296
Acute respiratory infections in immunocompromised hosts with myeloid malignancies and lymphoma and solid organ transplantation, 296
Acute respiratory infections in immunocompromised hosts with myeloid malignacies and lymphoma and solid organ transplantation, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignancies, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignancies and myeloid malignacies, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies and lymphoma, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies and myeloid malignacies, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies and myeloid malignacies and myeloid malignacies, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies and myeloid malignacies and myeloid malignacies and lymphoma, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies and myeloid malignacies and myeloid malignacies and lymphoma and solid organ transplantation, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies and myeloid malignacies and myeloid malignacies and lymphoma and solid organ transplantation and lymphoma, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies and myeloid malignacies and myeloid malignacies and lymphoma and solid organ transplantation and lymphoma and myeloid malignacies, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies and myeloid malignacies and myeloid malignacies and lymphoma and solid organ transplantation and lymphoma and myeloid malignacies and lymphoma, 296
Acute respiratory infections in immunocompromised hosts with solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies and myeloid malignacies and myeloid malignacies and lymphoma and solid organ transplantation and lymphoma and myeloid malignacies and lymphoma and myeloid malignacies, 296
Acute respiratory infections in immunocompr...
Arboviruses (continued)
Bunyaviridae, 495, 497, 499–503
clinical significance of, 502–502
complement fixation in diagnosis of, 506
detection and diagnosis of
epidemiologic surveillance and research, 505–507
routine diagnostics, 503–505
epidemiology of, 495–500
Flaviviridae, 495, 496, 498–503
geographic distribution of, 504
hemagglutination inhibition in diagnosis of, 505–506
IgM and IgG antibody detection for diagnosis of, 503–505
microarray technology in diagnosis of, 507
microsphere immunoassays in diagnosis of, 506
NGS in diagnosis of, 507
plaque-reduction neutralization in diagnosis of, 506
prevention of, 502–503
public health laboratory testing for, 585–589
real-time RT-PCR in diagnosis of, 506–507
RT-PCR in diagnosis of, 506
Togaviridae, 493–495, 500
treatment for, 502–503
vaccination for, 502–503
vector control for, 502
viral classification of, 493–495
virus isolation for, 505
Arenovirus
biology of, 515
clinical significance of, 517–518
detection and diagnosis of, 520
diagnostic best practices for, 521–522
epidemiology of, 516
prevention of, 519
taxonomy and characterization of, 11
treatment for, 519
viral classification of, 515
Aries, 125
Arteriviridae, database website for, 18
Arthropod-borne viral fevers, 7
ASCCP. See American Society of Colposcopy and Cervical Pathology
ASCP. See American Society of Clinical Pathology
ASRs. See Analyte specific reagents
Astrovirus
biology of, 313–314
clinical significance of, 316
database website for, 17
detection and diagnosis of
cell culture, 319
electron microscopy, 313, 319
immunoassays, 319
qRT-PCR assays, 319
RT-PCR assays, 319
serology, 318–319
epidemiology of, 315
specimen information for gastroenteritis with, 65
viral classification of, 313–314
ATLL. See Adult T-cell leukemia/lymphoma
Atypical and low-grade squamous cell lesion of cervix, 415
Austsky virus, 459
Australian bat lyssavirus, 13
Australian encephalitis, 9
Autoimmune diseases, EBV associated with, 391
Avian myeloblastosis virus (AMV), 130
B
Bacteriophages, 563
Baltimore classification
double-stranded DNA viruses, 5–6
double-stranded RNA viruses, 7
negative sense single-stranded RNA viruses, 11–13
positive sense single-stranded RNA viruses, 8–10, 14
single-stranded DNA viruses, 7
six groups of, 14
Banna virus, 7
Bar coding, 174
Barnah Forest virus (BFV), 10, 494
Bat-associated viruses, database website for, 17
Bayou virus, 11
BCA assay. See Biobarcode amplification assay
BD MAX, 124
BDNNA. See Branched DNA technology
BD ProbeTec herpes simplex viruses, 138, 139
BD Veritor System Flu A+B Immunoassay, 246–247
Betacoronavirus, 8
Betapapillomavirus
Betapapillomavirus
Borna disease virus
BGMK cells. See Buffalo green monkey kidney cells
Biobarcode amplification (BCA) assay, 248
Bioinformatics, 181–188
data storage for, 186
management of, 186
options for, 182–184
pipelines for viral, 184–186
quality assurance for, 186–188
software options, 183
tools for, 182–184
Bioinformatics pipeline, 174
Biological agents, safe transport of, 47
Biosafety in Microbiological and Biomedical Laboratories fifth edition
Biosafety cabinet (BSC), 53
Biosafety containment levels (BSL), 45
Biosafety containment levels (BSL)
Biosafety principles in, 41
laboratory safety with, 44
risk assessment for, 42
principles of, 41
scheme for, 169
laboratory safety with, 44
comparision of HC2 with, 170
principles of, 168–170
scheme for, 169
Breast cancer, EBV associated with, 390–391, 396
Bronchitis, 12–13
BSC. See Biosafety cabinet
BSL. See Biosafety containment levels
Butaviruses, 320
Buffalo green monkey kidney (BGMK) cells, 83
Bundhuyo ebolavirus, 12
Bunyaviridae, 495
clinical significance of, 501–502
epidemiology of, 499–500
family summarized, 497
vaccination for, 503
Bunyaviruses, caution in handling specimens from, 73
Buamba virus, 11
C
Cache Valley Virus, 83
Caliciviruses
biology of, 311
clinical significance of, 315
detection and diagnosis of
electron microscopy, 313, 317
immunoassays, 317
qRT-PCR assays, 317
RT-PCR assays, 317
serology, 317
epidemiology of, 314
viral classification of, 311
California (La Crosse) encephalitis
specimen information for neurological infections with, 62
clinical significance of, 434
diagnosis of, 435
seroprevalence of, 428–429, 430
BK virus (BKV)
Quantitative detection of, 159
specimen collection for, 66
specimen information for ocular infections with, 70
Black Creek Canal Virus, 11
Bleach, laboratory safety with, 44
Bloodborne Pathogen Standard, 44, 47
Blood transfusion, human herpes virus 8 with, 401
BMBL5. See Biosafety in Microbiological and Biomedical Laboratories fifth edition
Bocavirus, 7
Bolivian hemorrhagic fever, 19
Borna disease virus, 12
Borna virus, 12
Bourbon virus, specimen information for neurological infections with, 62
Bovine pseudo stomatitis virus, 459
Branched DNA technology (bDNA) application in virology laboratory of, 170
characteristics of, 168–170
comparison of HC2 with, 170
principles of, 168–170
scheme for, 169
Breed cancer, EBV associated with, 390–391, 396
Bronchitis, 12–13
BSC. See Biosafety cabinet
BSL. See Biosafety containment levels
Butaviruses, 320
Buffalo green monkey kidney (BGMK) cells, 83
Bundhuyo ebolavirus, 12
Bunyaviridae, 495
clinical significance of, 501–502
epidemiology of, 499–500
family summarized, 497
vaccination for, 503
Bunyaviruses, caution in handling specimens from, 73
Buamba virus, 11
Cytomegalovirus (CMV) (continued)
- prevention of, 374–375
- quantitative detection of, 145–146, 157–158
- repeat specimen collection for, 72
- serologic tests for, 375, 376, 378
- shell vial assay for, 376, 378
- specimen information for congenital infections with, 67
- specimen information for infectious mononucleosis with, 69
- specimen information for neurological infections with, 63
- specimen information for ocular infections with, 70
- specimen information for respiratory disease with, 60
- taxonomy and characterization of, 5
- transplant recipients with infection from, 381–382
- treatment for, 374–375
- tube culture for, 376
- viral classification of, 373
- virus culture for, 376, 378

Cytopathic effects (CPE), 42
- See also EIA.

Cytopathic effect-like effect (CLE), 95, 96

D
- Deep sequencing, 174
- Deer Tick virus, 496

Delmarvavirus, 14
- See also EIA.

Delaviridae, 13
- See also EIA.

Dengue fever, 9

Dengue hemorrhagic fever, 9, 19

Dengue virus, 496
- antibody detection for, 105
- clinical significance of, 500–501
- database website for, 17–19
- epidemiology of, 498
- public health laboratory testing for, 592
- specimen collection for, 66
- specimen information for hemorrhagic fevers with, 70
- specimen information for infections with joint pain with, 64
- specimen information for neurological infections with, 62
- taxonomy and characterization of, 9
- De novo assembly, 174
- Department of Health and Human Services (HHS), 35
- Department of Transportation (DOT), safe transport of specimens in, 48
- Dependovirus, 443
- clinical significance of, 447
- epidemiology of, 445
- taxonomy and characterization of, 7
- Depth of coverage, 174
- DFA. See Direct immunofluorescence
- Diagnostic Hybrids (DHI), 96
- Diarrhea, enteroviruses with, 284
- DiaSorin, 138, 140
- FilmArray BioThreat panel for, 249, 250
- future technology for, 249–250
- genus typing for, 192
- ReEBOV Antigen Rapid Test for, 249, 250
- specimen information for hemorrhagic fevers with, 70
- taxonomy and characterization of, 12
- Ebola Virus Rapid Antigen Diagnostic Test, 249, 250
- EVB. See Epstein-Barr virus
- EVB-associated, 389, 390, 395–396
- Enterovirus, 459
- Enterovirus hepatitis, 459
- EEEV. See Eastern equine encephalitis virus
- EIA. See Enzyme immunoassay
- Electron microscopy
- astroviruses diagnosis with, 313, 319
- caliciviruses diagnosis with, 313, 317
- enteric adenoviruses diagnosis with, 313, 319
- rotaviruses diagnosis with, 313, 318
- Enterophagocytosis
- enteral adenoviruses diagnosis with, 319
- rotaviruses diagnosis with, 318
- Electro spray ionization (ESI), 134–135
- PCR-ESI/MALDI, 134–135
- PCR-ESI-MS, 245
- ELISA. See Enzyme-linked immunosorbent assays
- ENVIS (Enzyme-linked inducible system), 86
- Emulsion PCR, 174
- Encephalitis, 14. See also California encephalitis virus, Eastern equine encephalitis virus, St. Louis encephalitis virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus
- Australian, 9
- enteroviruses with, 283
- Japanese, 9, 496, 499, 501
- Murray Valley, 9, 496, 499
- tick-borne, 9, 496
- Venezuelan, 62
- Encephalomyelitis, 14
- Enigma MiniLab influenza A/B & RSV, 248
- Enteral adenoviruses
- biology of, 314
- clinical significance of, 316
- detection and diagnosis of
- cell culture, 319
- electron microscopy, 313, 319
- electrophoresis, 319
- immunosays, 319–320
- PCR assays, 320
- real time PCR assays, 320
- serology, 319
- epidemiology of, 315
- viral classification of, 314
- Enteroviral encephalomyelitis, 8
- Enteroviral meningitis, 8
- Enteroviral vesicular pharyngitis, 8
- Enteroviruses, 277–287
- acute hemorrhagic conjunctivitis with, 283
- acute myocarditis caused by, 283
- age in risk for, 280–281
- antigenicity of, 279
- antivirals in treatment of, 284
- asymptomatic infections with, 281–284
- biology of, 277–279
- classification of, 277–279
- clinical syndromes with, 281–284
- diagnosis of, 277–279
- diaper rash with, 284
- encephalitis with, 283
- Epidemiology of, 279–281
- fever with maculopapular rash with, 283
- geography factors with, 280–281
- hand-foot-and-mouth disease with, 283
- herpangina with, 283
- history of discovery for, 277–278
- incubation times for, 281
- laboratory diagnostic of, 284–287
- mode of transmission for, 279–280
- molecular detection and characterization for, 285–286
- molecular variation with, 281
- neonatal enterovirus diseases with, 284
- neutralization of, 279
- nucleic acid detection assays for, 235


IgM anti-HBc for detection of, 348 markers in different stages of infection for, 342 microscopic detection of, 347 nucleic acid detection of, 348 nucleoside analogue for, 344 prevention of, 344 public health laboratory testing for, 589 quantitative detection of, 146, 157 serologic detection for, 105 serologic markers in patients with, 345 serologic tests for, 348 total anti-HBc for detection of, 348 treatment of, 344–345 worldwide distribution of, 343 Hepatitis C virus (HCV), 9 antibody detection assays for, 232–233 antiviral susceptibility testing for, 208, 212, 220–221 assays for genotyping assays, 357

clinical Indications for, 203
definitions, antiviral resistance, 203–204
variables of, 203–204
antiviral therapies for, 366
antiviral treatment for, 203–204
assays for, 204, 209–219
best practices for, 369–370
biological characteristics of, 363
clinical significance of, 364–365
detection and diagnosis of
algorithm for, 368
analytical, 367–368
antibody, 368
cell culture in, 81, 87
nucleic acid amplification tests, 368–369
postanalytical, 369
preanalytical, 367
diagnostic approach to, 60, 65
epidemiology of, 364
mechanism of action of therapies for,
366–367
mutations in UL23-gene of, 209–212
mutations in UL30-gene of, 213–219
prevention of, 366–367
specimen information for congenital
infections with, 67
specimen information for exanthems with,
61
specimen information for genital
infections with, 66
specimen information for neurological
infections with, 62
specimen information for ocular
infections with, 70
specimen information for respiratory
disease with, 60
viral classification of, 363
Herpesviridae, database website for, 18
Herpesviruses. See also Human herpesvirus
historical standards for diagnosis of, 458
Herpes zoster. See Zoster
HEV. See Hepatitis E virus
HHS. See Department of Health and
Human Services
HHV-6. See Human herpes virus 6
HHV-6A. See Human herpes virus 6A
HHV-6B. See Human herpes virus 6B
HHV-7. See Human herpes virus 7
HHV-8. See Human herpes virus 8
HI. See Hemagglutination inhibition
Histopathology
cytomegalovirus diagnosis with, 376, 378
for parapoxviruses lesion, 463
for poxviruses lesion, 461
for yatapoxviruses lesion, 464
HIV. See Human immunodeficiency virus
HMPV. See Human metapneumovirus
Holmes classification, 14
Hologic, 138
Horsepox virus, 459
HPV. See Human papillomavirus
HSV. See Herpes simplex virus
HTLV. See Human T-lymphotropic viruses
HTLV-1-associated myelopathy/tropical
spastic paraparesis (HAM/TSP), 531
treatment of, 532
Human adenovirus, database website for, 17
Human bocavirus (HBoV1-4), 443
clinical significance of, 446–447
diagnosis of, HBoV1, 447–448, 450
epidemiology of, 444–445
Human coronaviruses (HCoV)
best practices for, 271
biology of, 258–259
classification of, 258–259
clinical significance of, 264
diagnosis of, 269
epidemiology of, 261–262
prevention of, 266–267
relative importance of, 258–259,
261–262
taxonomy and characterization of, 8
treatment of, 266–267
Human herpesvirus
specimen information for exanthems with,
61
specimen information for ocular
infections with, 70
Human herpes virus 1, 5
Human herpes virus 2, 5
Human herpes virus 3, 5
Human herpes virus 4, 5
Human herpes virus 5, 5
Human herpes virus 6 (HHV-6)
AIDS in patients with, 69
antigen detection for diagnosis of, 404, 407
biology of, 399
clinical aspects of, 401–402
diagnostic best practices for, 407–408
DHLS associated with, 401
discovery of, 399
DNA for diagnosis of
in CSF, 405
in plasma, 404–405
in saliva, 405
epidemiology of, 402
immunocompetent hosts with infections from,
401
immunocompromised hosts with
infections from, 401–402
laboratory diagnosis for, 404–405, 407
multiple sclerosis associated with, 401
nucleic acid detection for diagnosis of,
404, 407
prevention of, 403
qualitative PCR for diagnosis of, 404, 407
qualitative RTPCR for diagnosis of, 404,
407
serology for diagnosis of, 404, 407
specimen selection for diagnosis of, 404
transcript detection in diagnosis of, 405,
407
transmission of, 400
treatment for, 403
viral load interpretations with diagnosis
of, 405
virus isolation for diagnosis of, 404, 407
Human herpes virus 6A (HHV-6A), 5
Human herpes virus 6B (HHV-6B), 5
Human herpes virus 7 (HHV-7), 399
antibody tests in diagnosis for, 405–406
biology of, 400
clinical aspects of, 402
diagnostic best practices for, 408
discovery of, 400
epidemiology of, 400–401
laboratory diagnosis for, 405–406
prevention of, 403
taxonomy and characterization of, 405
transmission of, 400–401
treatment for, 403
Human herpes virus 8 (HHV-8), 399
biology of, 400
blood transfusion with, 401
clinical aspects of, 402–403
diagnostic best practices for, 408
discovery of, 400
enzyme-linked immunosorbent assays in
diagnosis of, 406
epidemiology of, 401
immunofluorescence assays in diagnosis of,
406
Immunohistochemistry in diagnosis of,
406–407
Kaposi's sarcoma associated with,
402–403
laboratory diagnosis for, 406–407, 408
organ transplantation with, 401
PCR in diagnosis of, 407
prevention of, 403
serology for diagnosis of, 406, 408
In Situ hybridization in diagnosis of,
406–407
taxonomy and characterization of, 405
transmission of, 401
treatment for, 403
Human immunodeficiency virus (HIV), 14
Alere Q NAT system for, 248
antibody detection assays for, 233–235
antiviral susceptibility testing for,
221–222
best practices for, 540–541
biobarcode amplification assay for, 248
biology of, 527–529
clinical significance of, 530–531
coreceptor tropism determination with,
537
cytomegalovirus infection with, 381
database websites for, 17
detection and diagnosis of, 532–538
alternative specimens, 535–536
confirmation of, 536
in infants and children, 535
principal questions for, 533–538
rapid tests, 535–536
virus properties in, 536–537
when to test after exposure, 534–535
dried blood spot testing for, 248–249
epidemiology of, 529
future technology for, 248–249
genetic marker in predicting outcome of,
574
global distribution of, 529
HLA gene polymorphisms' effect on,
574
origin of, 527
preferred procedure for testing of, 540
prevention of transmission of, 532
public health laboratory testing for,
589–590
quantitative detection of, 145–146,
155–156
repeat specimen collection for, 71–72
replication characteristics of, 528
retroviral replication for, 527–528
screening in, 534
serologic detection for, 105
specimen information for congenital
infections with, 68
specimen information for infections with
joint pain with, 64
specimen information for infectious
mononucleosis with, 69
specimen information for retrovirus with,
66
transmission, 529
treatment for, 531–532
Human immunodeficiency virus (HIV), 14
(continued)
viral classification of, 527–529
viral load with, 537–538
virologic and immunologic parameters
for infection of, 530
virus diversity for, 527–528
window periods in early infection
of, 534
Human mastadenovirus
renaming of, 15
taxonomy and characterization of, 5
Human metapneumovirus (HMPV)
best practices for, 271
biology of, 257–258
classification of, 257–258
clinical significance of, 263
diagnosis of, 268
epidemiology of, 260
pneumonia, 13
prevention of, 265–266
relative importance of, 257–258, 260
specimen information for respiratory
disease with, 60
taxonomy and characterization of, 13
treatment of, 265–266
Human papillomavirus (HPV)
best practices for, 421–422
biology of, 413–414
classification of, 413–414
clinical significance of, 415
cutaneous, 415–416
cytological screening for, 60
detection and diagnosis of, 418–421
diseases associated to, 415
DNA-based assays for identification of
amplification-based assays, 420
antigen detection, 421
genotyping, 420–421
serology, 421
signal amplification, 419–420
epidemiology of, 414–415
FDA-approved assays for high-risk HPV
testing, 419
mucosal, 416–417
prevention of, 417–418
public health laboratory testing for, 590
specimen collection for, 419
specimen information for genital
infections with, 66
treatment of, 417–418
vaccines comparison for, 418
viral proteins functions with, 414
Human parainfluenza virus, 12–13
Human parvovirus, 9
Human picornavirus, taxonomy and
categorization of, 7
Human polyomaviruses
best practices for, 436–438
biology of, 427–428
clinical significance of, 431–433
detection and diagnosis of, 433–436
epidemiology of, 428–431
genome organization for, 427
life cycle of, 427–428
molecular epidemiology of, 429–431
prevention of, 433
seroepidemiology of, 428–429
structure of, 427
treatment for, 433
viral classification of, 427–428
Human polyomaviruses 6, 427
clinical significance of, 433
diagnosis of, 436
seroeprevalence of, 430
Human polyomaviruses 7, 427
clinical significance of, 433
diagnosis of, 436
seroeprevalence of, 430
Human polyomaviruses 9, 427
clinical significance of, 433
diagnosis of, 436
seroeprevalence of, 430
Human polyomaviruses 12, 427
clinical significance of, 433
diagnosis of, 436
seroeprevalence of, 430
Human respiratory syncytial virus, 13
Human T-lymphotropic viruses (HTLV)
best practices for, 404–412
biology of, 257–259
classification of, 257–259
clinical significance of, 263
epidemiology of, 260
etiology of, 260
life cycle of, 262
population studies of, 262
prevention of, 265–266
relative importance of, 257–258, 260
specimen information for exanthems
with, 61
specimen information for neurological
infections with, 63
specimen information for retroviruses
with, 66
treatment for, 404
viral classification of, 257
viral diversity of, 258–259
Western blot tests for, 539
Human T-tumor virus, 8, 20
Human virome
application in virology laboratory
strategies for, 562
technologies for studying, 562
next generation sequencing strategies
gut microbiota in, 563
composition of, 563
bacteriophages in, 563
Immunofluorescence (FA), 98
Immunofluorescence antibody assay (IFA)
diagnosis of, 318
Immunoglobulin M determinations
indirect methods of, 95
FDA approval of, 95
direct methods of, 95, 96, 101, 481–483, 551–552
FDA approval of, 95
indirect methods of, 95–96, 101
limitations of, 109
method for, 108–109
quality assurance for, 102, 109
staining using, 81
troubleshooting for, 109
Immunofluorescence antibody assay (IFA)
direct, 32
HHV-8 diagnosis with, 406
indirect, 95
characteristics of, 101
direct methods of, 95, 96, 101, 481–483, 551–552
Immunofluorescence (FA), 95–96
application of, 109
direct methods of, 109
characteristics of, 101
direct methods of, 95, 96, 101, 481–483, 551–552
Immunofluorescence antibody assay (IFA)
direct, 32
HHV-8 diagnosis with, 406
indirect, 95–96
characteristics of, 101
direct methods of, 95, 96, 101, 481–483, 551–552
Immunofluorescence antibody assay (IFA)
direct, 32
HHV-8 diagnosis with, 406
indirect, 95–96
characteristics of, 101
direct methods of, 95, 96, 101, 481–483, 551–552
Immunohistochemistry (IHC)
HHV-8 diagnosis with, 406–407
staining, 98–100
Immunostaining
blind, 83
cell culture, 83
IF staining, 81
Incubation
of cell cultures, 80–81
times for enteroviruses, 281
times for parechoviruses, 281
Indel, 174
Indiana virus, 13
Infections with joint pain
specimen information for, 64
Infectious mononucleosis
cytomegalovirus with, 380
EBV with, 388, 391, 393–394
specimen information for, 69
Inflammasome defects, 571
Inflammatory bowel diseases, EBV associated with, 391
Influenza A virus, 12
Influenza B virus, 12
Influenza C virus, 12
Influenza virus
Alere i Influenza A&B assay for, 247
tag antigen detection assays for, 230
antiviral susceptibility testing for, 204, 206, 208
best practices for, 270–271
biology of, 257
Cepheid GeneXpert Omni for, 247
classification of, 257
clinical significance of, 262–263
database website for, 17–18
diagnosis of, 267–268
cell culture in, 81, 88
Enigma MiniLab influenza A/B & RSV
to, 248
epidemiology of, 259–260
Focus Simplexa Flu A&B & RSV Direct
assay for, 247–248
future technology for, 247–248
neuraminidase inhibitors for, 206
PCR in screening of, 208
prevention of, 265
public health laboratory testing for, 590
relative importance of, 257–259
Roche Cobas Liat System for, 247
specimen information for respiratory
disease with, 60
taxonomy and characterization of,
human, 12
treatment of, 265
InGenius system, 125
Inoculation, of cell cultures, 80–81
Insert, 174
In Situ hybridization (ISH), HHV-8
diagnosis with, 406–407
Insulin-dependent diabetes mellitus, EBV
associated with, 391
International Air Transport Association
(IATA), 391
International Committee on Taxonomy
of Viruses (ICTV)
modern taxonomy from formation
of, 15
ninth report of, 15
nomenclature of, 15
sixth report of, 16
International Laboratory Accreditation
Cooperation (ILAC), 38
International Organization for
Standardization (ISO), 35
15189 standards, 37–39
accreditation pathway steps, 39
management review scope, 38
technical components, 38
differences between LAPs accreditation
and, 39
medical laboratories standards from,
37–39
International Statistical Classification
of Diseases and Related Health
Problems (ICD), 16
Ion Torrent FG, 178–180
Ion torrent sequencing technology, 177
Ishafan virus, 13
ISH. See In Situ hybridization
ISO. See International Organization for
Standardization
Isothermal nucleic acid amplification
methods, 137–143
future aspects of, 141–142
future perspectives on, 142–143
loop-mediated, 139–140
nicking endonuclease amplification
reaction, 140
present state of, 141–142
recombinase polymerase, 140–141
strand displacement, 139
strengths of, 141
transcription-based, 137–139
weaknesses of, 141
J
Japanese encephalitis virus, 9, 496
clinical significance of, 501
epidemiology of, 499
JC polyomavirus (JCPyV), 427
clinical significance of, 431
diagnosis of, 435
progressive multifocal
leukoencephalopathy associated
with, 438
PVAN associated with, 438
seroprevalence of, 428–429, 430
JC virus
specimen collection for, 69
specimen information for neurological
infections with, 63
specimen information for ocular
infections with, 70
The Joint Commission (TJC), 36–37
Jungle yellow fever, 19
Junin hemorrhagic fever, 11, 19
Junin virus, 11
K
Kaposi's sarcoma associated herpes virus
(KHSV)
HHV-8 associated with, 402–403
taxonomy and characterization of, 5
KFDV. See Kyasanur forest disease virus
KHSV. See Kaposi's sarcoma associated
herpes virus
KingFisher, 123
KingFisher Flex, 123
KingFisher ML, 123
KI polyomavirus (KIPyV), 427
clinical significance of, 432
diagnosis of, 435–436
seroprevalence of, 430
Kmer, 174
Kohnus virus, 9
Koch's postulates, 20
kPCR, 149
Kyasanur forest disease virus (KFDV), 9,
19, 496
L
Laboratories
certificate of compliance for, 36
regulation of testing in, 35–36
staff competency and requirements for,
27–28
test selection’s importance in, 59–60
Laboratory accreditation programs (LAPs),
39
Laboratory design, 51–55
bidding for, 52
biosafety cabinet in, 53
biosafety level requirements in, 52
CDC guidance for, 54
clinical virology elements needed in,
53–54
construction phase of, 52
LEAN concepts for, 55
occupancy phase of, 52–53
phases of, 51–53
planning for, 51
requirements for, 51
schematic for, 53, 54
workflow in, 54–55
Laboratory developed procedures (LDP),
153
Laboratory safety, 41–48
biosafety in, 44–46
principles of, 41
bleach in, 44
BSL levels in, 44–46
recommended practices for, 45
chemical safety, 43–44
culture of safety in, 41–42
disinfection in, 42–43
DMSO in, 44
electrical safety, 44
erthidium bromide in, 43–44
fire safety, 44
guanidinium compounds in, 43
hazard exposure with, 42
HEPA filter in, 45
personal protective equipment in, 45
risk assessment for, 42
safe transport of specimens in, 47–48
Safety Data Sheets for, 43
sterilization in, 42–43
waste disposal in, 48
work practices with, 42, 45, 46–47
La Crosse encephalitis. See California
encephalitis
La Crosse virus, 497
clinical significance of, 501
LAMP. See Loop-mediated isothermal
amplification
Langat virus, 9
LAPs. See Laboratory accreditation
programs
Lassa fever, 19
Lassa virus
specimen information for hemorrhagic
fevers with, 70
taxonomy and characterization of, 11
Lateral Flow. See Immunochromatography
LDP. See Laboratory developed procedures
Lebombo virus, 7
Leptovirus, 14
Leukoplaikia, 415
L.H.T. (Lwoff Horne Tournier) system, 14
Life Technologies SOLiD system, 175
Locked nucleic acid (LNA), 147
Loop-mediated isothermal amplification
(LAMP) advantages of, 141
application of, 140
commercially available kits for, 138
disadvantages of, 141
strengths of, 141
technique for, 139–140
weaknesses of, 141
Loaping ill virus, 9
Lujo virus, 11
Lwoff Horne Tournier. See L.H.T. system
Lymphocryptovirus, 5
Lymphocytic choriomeningitis virus
specimen information for neurological infections with, 63
taxonomy and characterization of, 11
Lymphomas
dult T-cell, 531, 532
EBV-associated, 389, 390, 395–396
Lymphoproliferative diseases, 388–389, 392, 394–396
Lysavirus, 13

M
M2000 sp, 123, 124
Maceine herpesvirus
M2000 sp, 123, 124
Machupo virus
Machupo hemorrhagic fever, 11, 19
Machupo virus
Machupo virus
Machupo hemorrhagic fever, 11, 19
Maculopapular rash, enterovirus with, 283
Malaniga virus, 10, 16
Madril virus, 11
Magnapure, 123
Magnapure Compact, 123
Major groove binding (MGB), 147
Magnapure, 123
See MALDI-TOF.
Madrid virus
Madariaga virus
Mamastrovirus
Mangapure 96, 124
Mangapure Compact, 123
Mastadenovirus
renaming of, 15
taxonomy and characterization of, 5
Mate pair read, 174
Matrix assisted laser/desorption ionization time of flight
Mamastrovirus, 9
Mammalian orthoreovirus, 7
Marburg marburgavirus, 12
Marburg virus
disease, 12, 19
specimen information for hemorrhagic fevers with, 70
taxonomy and characterization of, 12
Massively parallel pyrosequencing, 179
Massively parallel pyrosequencing, 179
Mastadenovirus
renaming of, 15
taxonomy and characterization of, 5
Mate pair read, 174
Matrix assisted laser/desorption ionization time of flight (MALDI-TOF), 134–135
Maxwell, 123
Mayaro virus (MAYV), 494
taxonomy and characterization of, 10
MCPyV. See Merkel cell polyomavirus
Measles virus, 12
best practices for, 304
biology of, 293
clinical significance of, 295–296
detection/diagnosis of, 298–301
epidemiology of, 294
IgM assay for, 299
immunofluorescence antibody assay for, 299
plaque-reduction neutralization assay for, 299
prevention of, 297
serological results for, 300
treatment for, 297
VerohfSLAM cell line for, 300
viral classification of, 293
Membrane ELA, 98, 99
characteristics of, 101
Meridian Bioscience, 138, 140
Merkel cell polyomavirus (MCPyV), 427
clinical significance of, 432
diagnosis of, 436
seroprevalence of, 430
MERS. See Middle East respiratory syndrome
Metagenomics, 174
Metapneumovirus, 13
MGB. See Major groove binding
MIAs. See Microsphere immunoassays
Microarray technology, arboviruses with, 507
Microsphere immunoassays (MIAs), arboviruses with, 506
Microwell-based ELA, 99–100
characteristics of, 101
Middle Eastern respiratory syndrome
Middle East respiratory syndrome, 8
Middle East respiratory syndrome (MERS), 83
cautions in handling specimens from, 73
DNA sequencing for, 192
public health laboratory testing for coronavirus, 592
specimen information for respiratory disease with, 60
MiniON, 179
MiSeq, 178, 179
MMLV. See Moloney murine leukemia virus
Molecular beacon, 132
Molecular phylogenetics, 19–20
Molecular testing, 31
Molluscipoxvirus, 5
Molluscipoxvirus molluscum contagiosum virus, 459
clinical signs, symptoms, and severity for, 462–463
diagnoses of, 462–463
differential diagnoses for, 463
electron micrograph of thin section of, 460
epidemiology of, 462
historic standards for diagnosis of, 458
incidence of, 462
pathogenesis of, 462
prevalence of, 462
transmission of, 462
Molluscum contagiosum virus
specimen information for exanthems with, 61
taxonomy and characterization of, 5
Moloney murine leukemia virus (MMLV), 130
Monkeypox virus, 459
historic standards for diagnosis of, 458
taxonomy and characterization of, 5
Morbilivirus, 12
Mucosal HPV
cervical cancer, 416–417
genital warts, 416
opharyngeal cancer, 416
respiratory papilloma, 416
Multiple sclerosis
EBV associated with, 391
HHV-6 associated with, 401
Multiplexed run, 174
Multiplex PCR, 133–134
Mumps virus
best practices for, 304–305
biology of, 293
clinical significance of, 296–297
detection/diagnosis of, 301
epidemiology of, 294–295
prevention of, 297–298
serological results for, 302
specimen information for neurological infections with, 63
specimen information for respiratory disease with, 60
taxonomy and characterization of, 13
treatment for, 297–298
viral classification of, 293
Mapapillomavirus,
Murray Valley encephalitis virus (MVEV), 496
epidemiology of, 499
taxonomy and characterization of, 9
MWPyV. See Malawi polyomavirus
Myasthenia gravis, EBV associated with, 391
Myelitis, 14

N
NAAT. See Nucleic acid amplification testing
NAI. See Neuraminidase inhibitors
Nairovirus, 11
NASBA. See Nucleic acid sequence-based amplification
Nasopharyngeal carcinoma, EBV associated with, 390, 392, 396
NAT. See Nucleic acid testing
National Center for Biotechnology Information's (NCBI), 173
National Reference Laboratories (NRLs) countries offering services for, 596–606
virology services of, 595–606
NEAR. See Nicking endonuclease amplification reaction
Neonatal enterovirus diseases, 284
Nephropathy, BK polyomavirus associated, 437–438
Nested PCR, 130–131
Neuraminidase inhibitors (NAI), influenza virus treatment with, 206
Neurological infections, specimen information for, 62–63
Neutralization
application of, 106
methods for, 106
quality assurance for, 107
troubleshooting for, 107
New Jersey polyomavirus (NJPyV-2013), 427
clinical significance of, 433
diagnosis of, 436
New Jersey virus, 13
New York virus, 11
Next generation sequencing (NGS)
arboviruses diagnosis with, 307
bridge amplification in, 175–176
as future technology, 243–244
gastrointestinal virus diagnosis with, 320
host contamination with, 180–181
human virome with, 561
implementation options for, 178
second generation, 175–176
sequencing increase from, 173
strategies for, 179–180
technologies and platforms for, 179
termology for, 174
third generation, 176–177
workflow for, 175–178
NextSeq, 179
NGS. See Next generation sequencing
Nicking endonuclease amplification reaction (NEAR)
advantages of, 142
application of, 140
commercially available kits for, 138
disadvantages of, 142
strengths of, 141
technique for, 140
weaknesses of, 141

Nipah virus
biology of, 515–516
clinical significance of, 518
detection and diagnosis of, 520
diagnostic best practices for, 522
epidemiology of, 517
prevention of, 519
taxonomy and characterization of, 12
treatment for, 519
viral classification of, 515–516
NJPyV-2013. See New Jersey polyomavirus
Norovirus
antigen detection assays for, 231–232
public health laboratory testing for, 590–591
specimen information for gastroenteritis with, 65
taxonomy and characterization of, 9
taxonomy determination for, 22
Norwalk virus, 9
NRLs. See National Reference Laboratories
Nucleic acid amplification testing (NAAT), 31
Chlamydia pneumoniae diagnosis with, 553
Chlamydia trachomatis diagnosis with, 550–551
cytomegalovirus diagnosis with, 377
for herpes simplex virus, 368–369
for varicella-zoster virus, 369
Nucleic acid-based molecular methods, cytomelagovirus diagnosis with, 377
Nucleic acid detection assays enterovirus in, 235
gastrointestinal viruses in, 236
hepatitis B virus detection with, 348
HHV-6 diagnosis with, 404, 407
respiratory viruses in, 235–236
Nucleic acid extraction automated methods for, 119–126
in-answer setup, 122–123
PCR mix setup function with, 124
performance of, 123–125
setup of master and reaction mix with, 121–122
automation of manual processes for, 121
everging technology for, 125–126
guanidinium thiocyanate-phenol-chloroform extraction for, 117–118
instruments that automate process for, 121
literature references comparing, 125
magnetic particle capture and robotics for, 121, 123
manual methods for, 117–119
NucliSens miniMAG system for, 119
performance comparison for systems of, 125
phenol-chloroform method for, 117
QIAamp DNA Mini and Blood Mini Kit for, 118–119
QIAamp Viral Mini Kit for, 118
semi-automated methods for, 117–119
TruTip technology for, 119, 120
validation of systems for, 126
Nucleic acid sequence-based amplification (NASBA)
advantages of, 141–142
application of, 137–138
commercially available kits for, 138
disadvantages of, 141–142
quantitative molecular methods with, strengths of, 141
weaknesses of, 141
Nucleic acid testing (NAT), 137
cytomegalovirus diagnosis with, 378–379
Nucleoside analogue (3TC), hepatitis B virus treatment with, 344
NucliSENS easyQ, 137, 138
NucliSens miniMAG system, 119
Nugapapillomavirus, 6
O
Occupational Safety and Health Administration (OSHA)
Bloodborne Pathogen Standard of, 44, 47
chemical safety outlined by, 43
Ocular infections, specimen information for, 70
Omsk hemorrhagic fever virus (OHFV), 9, 496
O’Nyong Nyong virus (ONNV), 494
taxonomy and characterization of, 10
Oral cancer, 415
Oral hairy leukoplakia, EBV associated with, 389–390, 392, 396
Oral lichen planus, 415
Oral squamous cell papilloma, 415
Orbivirus, 7
Orf virus, 459
taxonomy and characterization of, 6
Organ transplantation. See also Posttransplant lymphoproliferative disorder
cytomegalovirus infection in recipients of, 381–382
human herpes virus 8 with, 401
Orpharyngeal cancer, 416
Orpharyngeal squamous cell carcinoma, 415
Ortopoxvirus, 11
Orthobunyavirus, 11
Orthopoxviruses, 5, 458–461
Orthoreovirus, 7
Onguru virus, 7
OSHA. See Occupational Safety and Health Administration
Ovation RNA-Seq kit, 175
P
PacBio RS, 179
Paired-end read, 174
PAMPS. See Pathogen-associated molecular patterns
Papillomavirus, 18
Papillomaviruses, 21
Parainfluenza virus (PIV)
best practices for, 271
biology of, 258
classification of, 258
clinical significance of, 263
diagnosis of, 268
cell culture, 81–82, 88
epidemiology of, 260–261
human, 12–13
pneumonia, 12
prevention of, 266
relative importance of, 258, 260–261
specimen information for respiratory disease with, 60
taxonomy and characterization of human, 12–13
treatment of, 266
Paralytic myelitis, enteroviruses with, 282
Parapoxviruses
clinical signs, symptoms, and severity for, 462–463
dermis during infection from, 463
diagnoses of, 464
differential diagnoses for, 464
epidemiology of, 463–464
dermis during infection from, 463
geographical distribution of, 463
historical standards for diagnosis of, 458
incidence of, 463–464
lesion histopathology for, 463
pathogenesis of, 463
prevalence of, 463–464
taxonomy and characterization of, 6
transmission of, 463
Parechoviruses, 277–287
age in risk for, 280–281
antigenicity of, 19, 496
antivirals in treatment of, 284
asymptomatic infections with, 281–284
biology of, 277–279
classification of, 277–279
clinical syndromes with, 281–284
diagnostic best practices for, 287
diagnostics, 286–287
epidemiology of, 279–281
genotype factors with, 280–281
history of discovery for, 277–278
incubation times for, 281
laboratory diagnosis of, 284–287
modes for detection of, 285
mode of transmission for, 279–280
molecular detection and characterization for, 285–286
molecular variation with, 281
neutralization of, 279
pathogenesis with, 281–284
replication in cell culture of, 279
risk groups for, 280–281
seasonal factors with, 280–281
sex in risk for, 280–281
socioeconomic factors with, 280–281
structure of, 278–279
treatment and prevention of, 284
virus isolation and identification for, 285
Parvoviruses B19, 443
associations less common with, 451
commercial molecular assays for
detection of, 449
diagnosis of, 448–450
specimen information for congenital infections with, 68
specimen information for exanthems with, 61
specimen information for infections with
joint pain with, 62
specimen information for ocular infections with, 70
Parvoviruses
best practices for, 450
biology of, 443–444
Parvoviruses (continued)
clinical significance of, 446–447
detection and diagnosis of, 447–450
epidemiology of, 444–446
fetal hydrops with, 451
infection in immunocompromised patients with, 451
molecular characteristics of, 443–444
during pregnancy, 451
prevention of, 447
transient aplastic crisis with, 451
treatment for, 447
viral classification of, 443–444
Pathogen-associated molecular patterns (PAMPs), 568
Pathogen recognition receptors (PRRs), 567
PCR, See Polymerase chain reaction
PCR-ESI/MALDI, 134–135
PCR/ESI-MS. See Polymerase chain reaction/Electrospray ionization mass spectrometry
Penile cancer, 415
Pericarditis, enteroviruses with, 283
Personal protective equipment (PPE), 45
Penile cancer, 415
Picornaviruses, 13
Phred quality score, 174, 181
PCR/ESI-MS, 245
exanthems with information with, 61
gastroenteritis with information with, 65
HHV-6 with diagnosis with, 404, 407
HHV-8 with diagnosis with, 407
infections with joint pain information with, 64
influenza virus with screening with, 208
kPCR, 149
multiplex, 133–134
nested, 130–131
nucleic acid amplification by, 129–135
quantitative, 145, 146–149, 404, 407
real-time detection of nucleic acids by, 131–134, 137
enteric adenoviruses with diagnosis with, 320
quantitative molecular methods with,
reverse transcription, 137, 317–319
Taq with, 129
taques comparison for, 134
Polymerase chain reaction/Electrospray ionization mass spectrometry (PCR/ESI-MS), 245
Polyomaviruses
organization for genome, 427
life cycle of, 427–428
phylogenetic tree of, 428
taxonomy and characterization of, 6
Posttransplant lymphoproliferative disorder (PTLD), EBV associated with, 389, 392, 395
Powassan virus, 9, 496
specimen information for neurological infections with, 62
Poxviruses
biology of, 457–458
classification of, 457
clinical significance of, 458
clinical signs, symptoms, and severity for, 461–462
composition of, 457
database website for, 18
diagnoses of
DNA analysis, 466–467
EM, 466
future of, 467
histology, 466
historic standards for, 458
methods, 466–467
differential diagnoses for, 462
epidemiology of, 461–464
genera which infect humans, 459
geographical distribution of, 461
incidence of, 461
laboratory procedures for detecting, 465–467
lesion histopathology for, 461
life cycle of, 457–458
orthopoxviruses, 458–461
pathogenic for humans, 458–464
prevalence of, 461
prevention of, 465
public health laboratory testing for, 591
replication and spread in host of, 457–458
specimen collection, handling, and storage for, 465–466
transmission of, 461
treatment for, 465
virology of, 457, 459
PPE. See Personal protective equipment
PPI. See Pyrophosphate
Pregnancy, parvoviruses during, 451
Primate hocaparvovirus, 7
Primate erythroparvovirus renaming of, 15
taxonomy and characterization of, 7
Primate tetraparvovirus, 7
Primate T-lymphotropic virus 14
PRN. See Primal reduction neutralization
Procedure manual, 28–30
Procleix HEV, 138, 139
Procleix Parvo/LAV, 138
Procleix Ultrio, 138
Procleix Ultrio Elite, 138
Procleix Ultrio Plus, 138
Procleix WNV, 138
Proficiency testing, 32
Propawartos virus, 445
clinical significance of, 447
epidemiology of, 445–446
PRRs. See Pathogen recognition receptors
Pseudocoxovirus, 459
taxonomy and characterization of, 6
PTLD. See Posttransplant lymphoproliferative disorder
Public health laboratory (PHL)
clinical library collaboration with, 593
receiving results from, 592–593
role of, 585
scope of services by, 585–592
submitting specimens to, 592–593
testing performed by
arbovirus surveillance, 585–589
chikungunya, 592
dengue virus, 592
hepatitis B and C viruses testing, 592
HCV testing, 589–590
human papillomavirus testing, 590
influenza virus testing, 590
middle ear respiratory syndrome coronavirus, 592
norovirus testing, 590–591
poxviruses testing, 590–591
rabies virus testing, 591
respiratory viruses testing, 590
vaccine-preventable diseases, 591–592
virology services of, 585–593
Psamia virus, 11
PVAN, JCPyV associated with, 438
PyroMark Q24, 179
Pyrophosphate (PPI), 175
Pyrosequencing, 175
massively parallel, 179
Q
QIAamp DNA Mini and Blood Mini Kit, 118–119
QIAamp DNA Mini Kit, 118–119
QIAamp Viral Mini Kit, 118
Quantitative molecular methods (Viral)

- Quality trimming, 174
- Quantitative-mediated isothermal amplification (Q-LAMP)
  - advantages of, 142
  - application of, 140
  - commercially available kits for, 138
  - disadvantages of, 142
  - strengths of, 141
  - technique for, 139–140
  - weaknesses of, 141
- Quantitative molecular methods (Viral loads), 145–160
  - applications of, 155–159
  - assessment of, 149–155
  - for BK virus, 159
  - for CMV, 145–146, 157–158
  - digital PCR used in, 145, 149
  - for Epstein-Barr Virus, 145, 158
  - FDA-approved, 145–146
  - future implications of, 159–160
  - for Hepatitis B, 146, 157
  - for Hepatitis C, 146, 156–157
  - for HIV, 145–146, 155–156
  - kPCR used in, 149
  - laboratory developed procedures for, 153
  - limitations of, 149–153
  - NASBA used in, 147–149
  - PCR used in, 145, 146–149
  - performance of, 149–155
  - quantification of, 149–150
  - real-time PCR methods used in, 147
  - sigma metrics for precision and accuracy in, 153–155
- specimen integrity in, 151–152
- standardization in, 152–153
- variability of, 150–151
- QuickGene 810, 123
- Qx Amplified DNA Assays, 138
- R
  - Rabies virus, 13
  - antemortem diagnosis of animal, 485
  - biology of, 473–477
  - caution in handling specimens from, 73
  - clinical significance of, 477–478
  - control of, 479–480
  - epidemiology of human, 477
  - epizootiology of animal, 475–477
  - laboratory diagnosis of, 480–487
  - in animals, 480
  - antigen detection for, 481–483
  - best practices for, 487
  - direct immunofluorescence assay for, 481
  - dissection and sample preparation for, 481
  - histologic examination for, 483
  - human rabies, 486–487
  - molecular methods in, 483–485
  - rabies antibody assay for, 485–486
  - specimen collection, and preparation for, 480–481
  - virus isolation for, 483
  - pathogenesis and pathology of, 474–475
  - prevention of human, 478
  - prophylaxis of human, 478–479
  - public health laboratory testing for, 591
  - specimen information for neurological infections with, 63
  - treatment for, 478–480
  - variant typing, 485
  - viral classification of, 473–477
- Racoonpox virus, 459
- Race (Rescue, Alarm, Contain, and Extinguish), 44
- Rapid influenza diagnostic tests (RIDTs), 230, 231
  - as future technology, 246
- Read, 174
- Read length, 174
- Reagents, quality assurance for, 31
- Real-time PCR (RT-PCR), 131–134
  - enteric adenoviruses diagnosis with, 320
  - quantitative molecular methods with, 147
- reverse transcription, 137
- Real-time RT-PCR (qRT-PCR)
  - arboviruses diagnosis with, 506–507
  - astroviruses diagnosis with, 317
  - caliciviruses diagnosis with, 317
  - rotaviruses diagnosis with, 317
- Resequencing, 174
- Resistance testing
  - antiviral susceptibility in, 203–204
- HCV detection with, 357
- Respiratory disease
  - See also Respiratory viruses
  - enteroviruses with, 284
  - specimen information for respiratory disease with, 60
- Respiratory papilloma, 416
- Respiratory syncytial virus (RSV), 13
  - antigen detection assays for, 230–231
  - best practices for, 271
  - biology of, 257–258
  - classification of, 257–258
  - clinical significance of, 263
  - diagnosis of, 268
  - diagnosis of infections, cell culture, 88
  - epidemiology of, 260
  - pneumonia, 13
  - prevention of, 265–266
  - relative importance of, 257–258, 260
  - specimen information for respiratory disease with, 60
  - taxonomy and characterization of, 13
  - treatment of, 265–266
- Respiratory viruses
  - antigen detection assays for, 229–231
  - genetic marker in predicting outcome of, 574–575
  - human coronaviruses, 8, 258–259, 261–262, 264, 266–267, 269, 271
  - human metapneumovirus, 13, 60, 257–258, 260, 262, 263, 265–266, 268, 271
  - nucleic acid detection assays for, 235–236
  - parainfluenza virus, 12–13, 60, 81–82, 88, 258, 260–262, 263, 266, 268, 271
  - public health laboratory testing for, 590
  - rhinovirus, 9, 60, 88, 258, 261, 262, 263–264, 266, 268–269, 271
- Respirovirus, 12
- Reston ebolavirus, 12
- Retinoic acid-inducible gene 1 (RIG-1), 568
- Retroviruses, specimen information for, 66
- Reverse transcription qPCR (RT-PCR), 137
  - arboviruses diagnosis with, 506
  - astroviruses diagnosis with, 319
- Regulatory compliance, 35–39
  - agencies involved in, 35
- CAP in, 36–37
- CLIA in, 36–37
- ISO standards in, 37–39
- test complexity with, 35–36
- TJC in, 36–37
- Renal infections, specimen information for, 70
- Rescue, Alarm, Contain, and Extinguish. See Race
- Resequencing, 174
- Resistance testing
Reverse transcription qPCR (RT-qPCR), 137 (continued)
calciﬁvers diagnosis with, 317
HHV-6 diagnosis with, 404, 407
Rotaviruses diagnosis with, 318
Rhadinovirus, 5
Rheumatoid arthritis, EBV associated with, 61
Rhinovirus (RVH)
best practices for, 271
biology of, 258
classiﬁcation of, 258
clinical signiﬁcance of, 263–264
diagnosis of, 268–269
diagnosis of infections, cell culture for, 88
epidemiology of, 261
prevention of, 266
relative importance of, 258, 261
taxonomy and characterization of, 9
treatment of, 266
RIDDs. See Rapid inﬂuenza diagnostic tests
Rift Valley fever, 19, 497
clinical signiﬁcance of, 501–502
epidemiology of, 499
RIG-1. See Retinoic acid-inducible gene 1
RIG-1-like receptors (RLRs), 564, 569
R-mix, 84–85
R-mix Too, 84–85
RNA detection assays, HCV detection with, 355–357
Roche Cobas Liat System, 247
Roslovirus, 5
Ross River virus (RRV), 320
RSV.
RT-qPCR.
Rubella virus
best practices for, 305
biology of, 293–294
clinical signiﬁcance of, 297
detection/diagnosis of, 301–304
epidemiology of, 295
prevention of, 298
serological results for, 303
treatment for, 298
viral classiﬁcation of, 293–294
Rubivirus, 10
Rubulavirus, 13
RVB. See Rotavirus B
RVC. See Rotavirus C
RHH. See Rotavirus H
S
Sahá virus, 11
Safety Data Sheets, 43
Salivirus, 9
SAM/BAM, 174, 181
Sandfly fever Naples virus, 497
taxonomy and characterization of, 12
Sangassou virus, 16
Sanger sequencing, 173–175
Sapovirus
specimen information for gastroenteritis with, 65
taxonomy and characterization of, 9
Sapporo virus, 9
SARS. See Severe acute respiratory syndrome
Scalable target analysis routine (STAR), methods, 147
Scorpion molecules, 132
SDA. See Strand displacement ampliﬁcation
Seadornavirus, 7
Sealbox virus, 459
Semliki Forest virus (SFV), 494
taxonomy and characterization of, 10
Sentosa SX101, 123, 124
Seoul virus, 11
SeqlL, 179
Serologic methods, 105–114
cytomegalovirus diagnosis with, 375, 376, 378
enzyme immunoassay in, 109–111
HBV infections with, 105
hemagglutination inhibition in, 107–108
herpes simplex virus diagnosis with, 367–368
HIV infection with, 105
immunoﬂuorescence assays in, 108–109
immunoglobulin M determinations in, 111–113
neutralization in, 106–107
variella-zoster virus diagnosis with, 368, 369
western blot in, 113–114
Serology
astroviruses diagnosis with, 318–319
calciﬁvers diagnosis with, 317
Chlamydia pneumoniae diagnosis with, 553
enteric adenoviruses diagnosis with, 319
hepatitis B virus detection with, 348
HHV-6 diagnosis with, 404, 407
HHV-8 diagnosis with, 406, 408
HPV identiﬁcation with, 421
rotaviruses diagnosis with, 317
Severe acute respiratory syndrome (SARS), 8, 83
cautions in handling specimens from, 73
DNA sequencing for, 192
immunoassay for, 361
immunoassay with, 61
Severe fever and thrombocytopenia syndrome (SFTS), 333
Severe fever with thrombocytopenia syndrome virus (SFTSV), 497
epidemiology of, 500
SFTS. See Severe fever and thrombocytopenia syndrome
SFTSV. See Severe fever with thrombocytopenia syndrome virus
SFV. See Semliki Forest virus
Shell vial (centrifugation) technique, 83–86
cytomegalovirus diagnosis with, 376, 378
description of, 83–84
inoculation of, 84
reading procedure for, 84
sensitivity of, 83
test procedure for, 84
Sigea metrics, quantitative molecular
methods assessed with, 153–155
Signal ampliﬁcation methods
advantages of, 167
branched DNA technology
application in virology laboratory of, 170
characteristics of, 168–170
principles of, 168–170
scheme for, 169
challenge from target ampliﬁcation
methods, 147
comparison of technologies, 170
HPV identiﬁcation with, 421
hybrid capture technology
application in virology laboratory of, 168
characteristics of, 167–168
principles of, 167–168
scheme for, 168
Simplexvirus, 5
Sindbis virus (SINV), 494
clinical signiﬁcance of, 500
epidemiology of, 498
taxonomy and characterization of, 10
Single-molecule, real-time (SMRT) technology, 176
Single nucleotide polymorphisms (SNPs), 568
Sin Nombre virus, 11
SINV. See Sindbis virus
Sixth disease. See Exanthema subitum
Sjögren’s syndrome, EBV associated with, 391
Skankbox virus, 459
SLEV. See St. Louis encephalitis virus
Smallpox, taxonomy and characterization of, 5
Smooth muscle tumors, EBV associated with, 391, 392, 396
SMRT technology. See Single-molecule, real-time technology
SNP analysis, 174
SNPs. See Single nucleotide polymorphisms
Sofia Inﬂuenza A+B Fluorescent
immunoassay, 246
Specimen collection, 59–74
for congenital infections, 67–68
for exanthems, 61
future considerations for, 73–74
Downloaded from www.asmscience.org by
IP: 54.70.40.11
Viral antigen detection, 95–103
application of, 100–102
basic concepts of, 95–100
diagnostic hybrids proficiency panel
in, 96
enzyme immunoassay, 98–100, 101
immunochromatography, 96–98, 101
immunofluorescence, 95–96, 101
immunohistochemical staining, 98–100
membrane EIA, 98, 99, 101
microwell-based EIA, 99–100, 101
quality assurance for, 102–103
reporting for, 102–103
tube EIA, 99–100
Viral diseases
diagnosis of, 572–575
genetic factors in susceptibility to, 568–572
complement deficiency, 571
C-type lectins, 568, 569–571
hypogammaglobulinemia, 571
immune cell deficiencies, 571
inflammasome defects, 571
RLRs, 568, 569
tLRs, 568, 569
host response patterns in diagnostics for, 573
human susceptibility and response to, 567–575
genetic factors in, 568–572
receptor binding with, 569
immune response to, 568
monitoring of, 572–575
predicting outcomes for, 572–575
monitoring host factors in, 573
single-molecule markers for, 572
Viral intestinal infection, 8
taxonomy and characterization of, 7
Viral isolation, 79–90
cell cultures types in, 79, 80
common viruses in, 86–88
diagnostic applications of, 89–90
equipment needed for, 79–80
identification of, 83
quality assurance for, 88–89
sensitivity in, 79
supplies needed for, 79–80
troubleshooting for, 88–89
Viral loads. See Quantitative molecular methods
Viral meningitis, enteroviruses with, 282–283
Viral microarray-based assays, 245
Viral serology, quality assurance for, 31–32
Viral transport medium (VTM), 72
Viral warts, taxonomy and characterization of, 6
Virome, 174. See also Human virome
Viromics, 189
Viruses
biological pressures driving evolution of, 4
classification methods for, 14–15
defined, 3
escape theory of, 3
factors separating from other forms of life, 4
historical description of, 3
quality assurance in study of, 27
taxa infecting humans, 4
taxonomy of, 3–22
viral proteins functions with, 414
Virus genotyping, 191–192
Volepox virus, 459
VPDs. See Vaccine-Preventable Diseases
VTM. See Viral transport medium
Valvar cancer, 415
VZV. See Varicella-zoster virus
W
WEEV. See Western equine encephalitis virus
Wesselsbron, 9
Western blot
application of, 113–114
HTLV testing with, 538–539
limitations of, 113
method for, 113
quality assurance for, 113
Western equine encephalitis virus
(WEEV), 494
epidemiology of, 498
specimen information for neurological infections with, 62
taxonomy and characterization of, 10
West Nile virus (WNV), 496
clinical significance of, 501
database website for, 18
epidemiology of, 498–499
specimen collection for, 66
specimen information for neurological infections with, 62
taxonomy and characterization of, 9
WGS. See Whole-genome shotgun
Whataroa virus (WHAV), 494
Whole-genome shotgun (WGS), human
virome with, 561
WNV. See West Nile virus
WU polyomavirus (WUPyV), 427
clinical significance of, 432
diagnosis of, 435–436
seroprevalence of, 430
X
X-linked lymphoproliferative syndrome
(XLP), 571
EBV associated with, 389, 392, 395
Y
Yaba Monkey, 459
Yaba monkey tumor virus, 6
Yatapoxviruses
clinical signs, symptoms, and severity for, 464
diagnoses of, 464
differential diagnoses for, 464–465
epidemiology of, 464
geographical distribution of, 464
historic standards for diagnosis of, 458
incidence of, 464
lesion histopathology for, 464
pathogenesis of, 464
prevalence of, 464
taxonomy and characterization of, 6
transmission of, 464
Yellow fever, 9, 19
jungle, 19
sylvatic, 19
urban, 19
Yellow fever virus (YFV), 496
clinical significance of, 501
epidemiology of, 499
Z
Zaire ebolavirus, 12
Zero-mode waveguide (ZMW), 176
Zika virus, 496
epidemiology of, 499
taxonomy and characterization of, 9
ZMW. See Zero-mode waveguide
Zoster (Herpes zoster), taxonomy and characterization of, 5